193 related articles for article (PubMed ID: 22420004)
1. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression.
Kasuki L; Vieira Neto L; Wildemberg LE; Colli LM; de Castro M; Takiya CM; Gadelha MR
Endocr Relat Cancer; 2012 Jun; 19(3):L25-9. PubMed ID: 22420004
[No Abstract] [Full Text] [Related]
2. Octreotide LAR for the treatment of acromegaly.
Vallette S; Serri O
Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):783-93. PubMed ID: 18611118
[TBL] [Abstract][Full Text] [Related]
3. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern.
Kasuki L; Wildemberg LE; Neto LV; Marcondes J; Takiya CM; Gadelha MR
Eur J Endocrinol; 2013 Aug; 169(2):217-23. PubMed ID: 23749849
[TBL] [Abstract][Full Text] [Related]
5. Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression.
Kasuki L; Colli LM; Elias PC; Castro Md; Gadelha MR
Arq Bras Endocrinol Metabol; 2012 Nov; 56(8):501-6. PubMed ID: 23295289
[TBL] [Abstract][Full Text] [Related]
6. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
Wildemberg LE; Neto LV; Costa DF; Nasciuti LE; Takiya CM; Alves LM; Rebora A; Minuto F; Ferone D; Gadelha MR
J Endocrinol Invest; 2013 Jan; 36(1):38-43. PubMed ID: 22472799
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
8. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant.
Joshi K; Daly AF; Beckers A; Zacharin M
Horm Res Paediatr; 2018; 90(3):196-202. PubMed ID: 29953972
[TBL] [Abstract][Full Text] [Related]
9. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
10. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
11. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide.
Casar-Borota O; Heck A; Schulz S; Nesland JM; Ramm-Pettersen J; Lekva T; Alafuzoff I; Bollerslev J
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1730-9. PubMed ID: 24092823
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly.
Gatto F; Feelders RA; van der Pas R; Kros JM; Waaijers M; Sprij-Mooij D; Neggers SJ; van der Lelij AJ; Minuto F; Lamberts SW; de Herder WW; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2013 Jan; 98(1):E66-71. PubMed ID: 23118420
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
14. Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
Saveanu A; Gunz G; Dufour H; Enjalbert A; Culler MD; Jaquet P
J Endocrinol Invest; 2003; 26(8 Suppl):4-7. PubMed ID: 15233203
[No Abstract] [Full Text] [Related]
15. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary adenoma from acromegalic patients: good correlation with preoperative response to octreotide.
Takei M; Suzuki M; Kajiya H; Ishii Y; Tahara S; Miyakoshi T; Egashira N; Takekoshi S; Sanno N; Teramoto A; Osamura RY
Endocr Pathol; 2007; 18(4):208-16. PubMed ID: 17987403
[TBL] [Abstract][Full Text] [Related]
17. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.
Jaffrain-Rea ML; Rotondi S; Turchi A; Occhi G; Barlier A; Peverelli E; Rostomyan L; Defilles C; Angelini M; Oliva MA; Ceccato F; Maiorani O; Daly AF; Esposito V; Buttarelli F; Figarella-Branger D; Giangaspero F; Spada A; Scaroni C; Alesse E; Beckers A
Endocr Relat Cancer; 2013 Oct; 20(5):753-66. PubMed ID: 23940012
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptors in GH-secreting pituitary adenomas--their relationship to the response to octreotide.
Pawlikowski M; Pisarek H; Kunert-Radek J; Radek M
Endokrynol Pol; 2008; 59(3):196-9. PubMed ID: 18615392
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
